Table 2.
Confirmation cohorts
| Survival Cohort (n=156) | Contemporary Cohort (n=52) | P-value | |
|---|---|---|---|
| Age, mean (SD) | 66.1 (7.6) | 68.7 (5.7) | 0.01 |
| Sex, n (% male) | 100 (64.1%) | 43 (82.7%) | 0.02 |
| Smoker, n (% ever) | 104 (66.7%) | 32 (61.5%) | 0.9 |
| FVC% predicted, mean (SD) | 66.3 (17.5) | 73.2 (16.6) | 0.01 |
| DLCO% predicted, mean (SD) | 50.8 (15.9) | 42.8 (11.9) | <0.01 |
| On immunosuppression, n (%) | 45 (28.9%) | 0 | - |
| On antifibrotic, n (%) | 0 | 22 (42.3%) | - |
| Survived up to 5-years, % | 30.1% | *17.3% | 0.10 |
| Time to death in days, mean (SD) | 1326.9 (1403.6) | 1269.0 (994.8) | 0.8 |
| Time to death in years, mean (SD) | 3.6 (3.8) | 3.5 (2.7) | 0.8 |
| BAL % Neutrophil, mean (SD) | 8.8 (9.6) | unknown | - |
| GAP score, mean (SD) | 3.1 (1.1) | 4.4 (1.2) | <0.01 |
Table 3. SD: standard deviation, FVC: forced vital capacity, DLCO: diffusion capacity for carbon monoxide, BAL: bronchoalveolar lavage, GAP: gender, age and physiology score.
*
Survival data only available for the 50-week period of observation for those patients in the validation dataset whose samples were derived from WRAP-IPF.